Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 94, 103380
Abstract
No abstract availableKeywords
Funding Information
- Ministry of HRD, Govt. of India
This publication has 123 references indexed in Scilit:
- Estrogen receptor beta in breast cancerMolecular and Cellular Endocrinology, 2014
- Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cellsOrganic & Biomolecular Chemistry, 2012
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive markerBritish Journal of Cancer, 2009
- Predicting druggable binding sites at the protein–protein interfaceDrug Discovery Today, 2009
- Structural basis for androgen specificity and oestrogen synthesis in human aromataseNature, 2009
- Minireview: The Intersection of Steroid Receptors with Molecular Chaperones: Observations and QuestionsMolecular Endocrinology, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancerBreast Cancer Research and Treatment, 2007
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002